J&J, MeiraGTx partner on gene therapies for rare retinal diseases

By Mark Zipkin | Jan 31, 2019 | 10:14 PM GMT

Janssen Pharmaceuticals Inc. picked up its first clinical gene therapies Thursday in a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx added $2.84 (30%) to $12.38 on Thursday.

Janssen gains rights to develop

Read the full 395 word article

How to gain access

Continue reading with a
two-week free trial.